Paraplexin solution for injection 5 mg/ml ampoule 1 ml No. 10

Paraplexin ® injection solution is used for the following indications:

Composition

Active ingredient: Ipidacrine hydrochloride monohydrate (1 ml of solution contains 5 mg of Ipidacrine hydrochloride monohydrate calculated on the anhydrous basis).

The excipient is water for injection.

Contraindication

Method of application

The solution for injection is administered intramuscularly or subcutaneously. The dose and duration of treatment should be determined individually, depending on the severity of the disease.

Peripheral nervous system diseases

Mono- and polyneuropathies of various genesis: subcutaneously or intramuscularly administer 5-15 mg 1-2 times a day, the course of treatment is 10-15 days (in severe cases - up to 30 days); then treatment should be continued with the tablet form of Ipidacrin.

Myasthenia and myasthenic syndrome: subcutaneously or intramuscularly inject 5-30 mg 1-3 times a day with subsequent transition to tablet form. The total course of treatment is 1-2 months. If necessary, the treatment can be repeated several times with a break between courses of 1-2 months.

Central nervous system diseases

Bulbar palsies and paresis: subcutaneously and intramuscularly 5-15 mg 1-2 times a day, course of treatment - 10-15 days, if possible, switch to tablet form.

Recovery period for organic CNS lesions

Intramuscularly 10-15 mg 1-2 times a day, the course of treatment is up to 15 days, then 1-2 times a day if possible.

Application features

Pregnant women

"Paraplexin ®" increases uterine tone and can cause premature birth, so the use of the drug is contraindicated during pregnancy.

The use of the drug is contraindicated during breastfeeding.

Children

There are no systematic data on the use of the parenteral form of Ipidacrine hydrochloride in children (under 18 years of age), therefore it should not be used in children.

Drivers

During the treatment period, you should refrain from driving a car, as well as from engaging in potentially dangerous activities that require increased concentration and quick reactions.

Overdose

Symptoms: bronchospasm, lacrimation, increased sweating, constriction of the pupils, nystagmus, increased peristalsis of the gastrointestinal tract, spontaneous defecation and urination, vomiting, jaundice, bradycardia, conduction disorders, arrhythmias, decreased blood pressure, anxiety, agitation, a feeling of fear, ataxia, convulsions, coma, speech disorders, drowsiness, general weakness.

Treatment: symptomatic therapy should be used, m-cholinoblockers should be used: atropine, cyclodol, metacin, and others.

Side effects

Cardiovascular system: increased heartbeat, decreased heart rate.

From the nervous system: when using high doses - dizziness, headache, drowsiness, general weakness, convulsions.

On the part of the respiratory system: increased secretion of bronchial secretions, bronchospasm.

On the part of the digestive system: increased salivation, nausea, when using high doses - vomiting, diarrhea, jaundice, pain behind the sternum.

Skin and subcutaneous tissue disorders: increased sweating; allergic reactions, including rash, itching, urticaria, angioedema.

From the reproductive system: increased uterine tone.

In case of development of undesirable side effects the dose should be reduced or the use of the drug should be interrupted for a short time (for 1-2 days). Salivation and decrease in heart rate can be reduced by m-holinoblokatorov (atropine, etc.).

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C, out of the reach of children. Do not freeze.

Shelf life - 2 years.